

Capitol Gastroenterology Consultants Medical Group, Inc.

Carmichael

William K. Y. Chen, M.D.
Kuldip S. Sandhu, M.D., F.A.C.P.
David Schneiderman, M.D., F.A.C.P.
David W. Watson, M.D., F.A.C.P.
Sidney Yassinger, M.D.
Todd W. Zimmerman, M.D., F.A.C.P.

Roseville

Theodor Feinstat, M.D.
Sayed Hussain, M.D.
Roy M. Matsuyama, M.D.
Nasir Moloo, M.D.
Khosrow Nasr, M.D.

8 7 6 4 '00 NOV 20 A7:59

November 14, 2000

Dockets Management Branch, FDA
Dept. of Health and Human Services
Room 1-23
12420 Parklawn Drive
Rockville, Maryland 20857


Dear Food and Drug Administration,

I have first-hand experience that Lotronex provides multisymptom relief for female patients with diarrhea-predominant IBS and would like to express my support.

This is the first prescription product approved for IBS in over 15 years, and gives the patients an option of something that really works.

When used in the appropriate patients Lotronex has given significant relief of the pain and discomfort associated with IBS. Of course, Lotronex should not be used in patients who are constipated or have a history of constipation or ischemic colitis as spelled out in the package insert. But in the appropriate patient types Lotronex has succeed in giving relief.

Thank you



Roy M. Matsuyama, MD

00P-1499

C 19